Trying to build a cancer center in the middle of a saturated market should be difficult enough.
With a month to go before his Dec. 1 start date as president of MD Anderson Cancer Center, Peter Pisters reflected on the challenges that await him in Houston.
Ten years ago, the formation of the Komen Tissue Bank at the Indiana University Melvin and Bren Simon Cancer Center was met with skepticism.
When Eric Karlson's lymphoma went into complete regression in 2009, Steven Rosenberg and James Kochenderfer knew they were making history—for the first time, they had cured a patient by using genetically modified cell therapy, specifically, anti-CD19 CAR-T cells.
It may not be possible to point to definitive causes of the turnover in the executive offices of top academic cancer centers. However, the job of a center director is changing, said Robert Ferris, director of the University of Pittsburgh UPMC Hillman Cancer Center.
The idea that led to the site-agnostic indication for Keytruda (pembrolizumab) came from the academic oncologists, who ended up defining the biologic mechanism of activity of this class of drugs.
The application for approval of Keytruda (pembrolizumab) was based on internal discussions within FDA as well as working “proactively with the sponsor to submit this application,” said Steven Lemery, associate director, Division of Oncology Products 2, FDA Office of Hematology and Oncology Products.
Through the controversies triggered by the National Dialogue on Cancer, John Seffrin relied on his ACS ally Allan Erickson.
The Foundation for Tobacco-Free World is unlikely to win hearts and minds in the tobacco control community, said Matt Myers, president of the Campaign for Tobacco-Free Kids.
As the inaugural chair of the University of California Cancer Consortium, Alan Ashworth has to do a little cheerleading and a lot of pushing for integration of the electronic health records across the UC cancer centers.
